In vivo activity of optimized apidaecin and oncocin peptides against a multiresistant, KPC-producing klebsiella pneumoniae strain

Protein and Peptide Letters

Volumn 21, Issue 4, 2014, Pages 368-373

  Ostorházi, Eszter ^a   Nemes Nikodém, Éva ^a   Knappe, Daniel ^b   Hoffmann, Ralf ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Antibacterial peptides; Api88; Klebsiella pneumoniae carbapenemase (KPC); Murine infection model; Onc72

Indexed keywords

ANTIMICROBIAL PEPTIDE APIDAECIN API88; ANTIMICROBIAL PEPTIDE ONCOCIN ONC72; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIUM ISOLATION; CD-1 MOUSE; COLONY FORMING UNIT; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; FEMALE; HUNGARY; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MOUSE; MULTIDRUG RESISTANT CARBAPENEMASE PRODUCING KLEBSIELLA PNEUMONIAE; NONHUMAN; PROCESS OPTIMIZATION; REPEATED DRUG DOSE; SURVIVAL RATE; SURVIVAL TIME; UPREGULATION;

AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIAL PROTEINS; BETA-LACTAMASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICE; MOLECULAR SEQUENCE DATA;

EID: 84896385995     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/09298665113206660107     Document Type: Article

References (27)

1. Peleg, A.Y.; Hooper, D.C. Hospital-acquired infections due to Gram-negative bacteria. N. Engl. J. Med., 2010, 362, 1804-1813.
2. Falagas, M.E.; Karageorgopoulos, D.E. Extended-spectrum betalactamases- producing organisms. J. Hosp. Infect., 2009, 73, 345-354.
3. Coque, T.M.; Baquero, F.; Canton, R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro. Surveill., 2008, 13, 47.
4. Nordmann, P.; Cuzon, G.; Naas, T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis., 2009, 9, 228-236.
5. Munoz-Price, L.S.; Quinn, J.P. The spread of Klebsiella pneumoniae carbapenemases: a tale of strains, plasmids, and transposons. Clin. Infect. Dis., 2009, 49, 1739-1741.
6. Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature, 2002, 415, 389-395.
7. Casteels, P.; Ampe, C.; Jacobs, F.; Vaeck, M.; Tempst, P. Apidaecins: antibacterial peptides from honeybees. EMBO J., 1989, 8, 2387-2391.
8. Knappe, D.; Piantavigna, S.; Hansen, A.; Mechler, A.; Binas, A.; Nolte O.; Martin, L.L.; Hoffmann, R. Oncocin (VDKPPYLPRPRPPRRIYNR-NH2): a novel antibacterial peptide optimized against Gram-negative human pathogens. J. Med. Chem., 2010, 53, 5240-5247.
9. Czihal, P.; Knappe, D.; Fritsche, S.; Zahn, M.; Berthold, N.; Piantavigna, S.; Müller, U.; Van Dorpe, S.; Herth, N.; Binas, A.; Köhler, G.; De Spiegeleer, B.; Martin, L.L.; Nolte, O.; Sträter, N.; Alber, G.; Hoffmann, R. Api88 is a novel antibacterial designer peptide to treat systemic infections with multidrug-resistant Gram-negative pathogens. ACS Chem. Biol., 2012, 7, 1281-91.
10. Knappe, D.; Fritsche, S.; Alber, G.; Köhler, G.; Hoffmann, R.; Müller, U. Oncocin derivative Onc72 is highly active against Escherichia coli in a systemic septicaemia infection mouse model. J. Antimicrob. Chemother., 2012, 67, 2445-51.
11. Tóth, Á.; Damjanova, I.; Puskás, E.; Jánvári, L.; Farkas, M.; Dobák, A.; Böröcz, K.; Pászti, J. Emergence of a colistin-resistant KPC-2-producing Klebsiella pneumoniae ST258 clone in Hungary. Eur. J. Clin. Microbiol. Infect. Dis., 2010, 29, 765-769.
12. www.eucast.org
13. Otvos, L. Jr.; Wade, J.D.; Lin, F.; Condie, B.A.; Hanrieder, J.; Hoffmann, R. Designer antibacterial peptides kill fluoroquinoloneresistant clinical isolates. J. Med. Chem., 2005, 48, 5349-59.
14. Otvos, L. Jr.; Rogers, I.O.M.E.; Consolvo, P.J.; Condie, B.A.; Lovas, S.; Bulet, P.; Blaszczyk-Thurin, M. Interaction between heat shock proteins and antimicrobial peptides. Biochemistry, 2010, 39, 14150-14159.
15. Zhou, Y.; Chen, W.N. iTRAQ-coupled 2-D LC-MS/MS analysis of cytoplasmic protein profile in Escherichia coli incubated with apidaecin. IB. J. Proteomics., 2010, 75, 511-516.
16. Hancock, R.E.; Scott, M.G. The role of antimicrobial peptides in animal defenses. Proc. Natl. Acad. Sci. USA, 2010, 97, 8856-8861.
17. Hansen, A.; Schäfer, I.; Knappe, D.; Seibel, P.; Hoffmann, R. Intracellular toxicity of proline-rich antimicrobial peptides shuttled into mammalian cells by the cell-penetrating peptide penetratin. Antimicrob. Agents Chemother., 2012, 56, 5194 -5201.
18. Szabo, D.; Ostorhazi, E.; Binas, A.; Rozgonyi, F.; Kocsis, B.; Cassone, M.; Wade, J.D.; Nolte, O.; Otvos, L. Jr. The designer prolinerich antibacterial peptide A3-APO is effective against systemic Escherichia coli infections in different mouse models. Int. J. Antimicrob. Agents, 2010, 35, 357-361.
19. Benincasa, M.; Pelillo, C.; Zorzet, S.; Garrovo, C.; Biffi, S.; Gennaro, R.; Scocchi, M. The proline-rich peptide Bac7(1-35) reduces mortality from Salmonella typhimurium in a mouse model of infection. BMC Microbiol., 2010, 10, 178.
20. Knappe, D.; Fritsche, S.; Alber, A.; Köhler, G.; Hoffmann, R.; Müller, U. Oncocin derivative Onc72 is highly active against Escherichia coli in a systemic septicaemia infection mouse model. J. Antimicrob. Chemother., 2012, 672, 445-2451.
21. Fumarola, D.; Marcuccio, L.; Fransvea, P.; Pasquetto, N.; Miragliotta, G., Brienza, A. Attempted protection against experimental endotoxic shock. G. Batteriol. Virol. Immunol., 1975, 68, 224-230.
22. Berthold, N.; Czihal, P.; Fritsche, S.; Sauer, U.; Schiffer, G.; Knappe, D.; Alber, G.;Hoffmann, R. Novel apidaecin 1b analogs with superior serum stabilities for treatment of infections by Gramnegative pathogens. Antimicrob Agents Chemother., 2013, 57, 402-409.
23. Knappe, D.; Kabankov, N.; Hoffmann R. Bactericidal oncocin derivatives with superior serum stabilities. Int. J. Antimicrob. Agents, 2010, 37,166-170.
24. Falagas, M.E.; Rafailidis, P.I.; Matthaiou, D.K. Resistance to polymyxins: Mechanisms, frequency and treatment options. Drug Resist. Updat., 2010, 13, 132-138.
25. Kline, T.; Trent, M.S.; Stead, C.M.; Lee, M.S.; Sousa, M.C.; Felise, H.B.; Nguyen, H.V.; Miller, S.I. Synthesis of and evaluation of lipid A modification by 4-substituted 4-deoxy arabinose analogs as potential inhibitors of bacterial polymyxin resistance. Bioorg. Med. Chem. Lett., 2008, 18, 1507-1510.
26. Ostorhazi, E.; Holub, M.C.; Rozgonyi, F.; Harmos, F.; Cassone, M.; Wade, J.D. Otvos, L. Jr. Broad-spectrum antimicrobial efficacy of peptide A3-APO in mouse models of multidrug-resistant wound and lung infections cannot be explained by in vitro activity against the pathogens involved. Int. J. Antimicrob. Agents, 2011, 37, 480-484.
27. Fritsche, S.; Knappe, D.; Berthold, N.; von Buttlar, H.; Hoffmann, R.; Alber, G. Absence of in vitro innate immunomodulation by insect- derived short proline-rich antimicrobial peptides points to direct antibacterial action in vivo. J. Pept. Sci., 2012, 18, 599-608